Pharma Tips

FDA approves Raptor's orphan disease drug Procysbi

By: Pharma News | Views: 1182 | Date: 03-May-2013

The US Food and Drug Administration have approved Raptor Pharmaceuticals' Procysbi for the management of a rare genetic disease called nephropathic cystinosis.

FDA approves Raptor's orphan disease drug Procysbi

The US Food and Drug Administration have approved Raptor Pharmaceuticals' Procysbi for the management of a rare genetic disease called nephropathic cystinosis.

Cystinosis affects 500 patients in the USA (and 3,000 worldwide) and causes a protein building block called cystine to build up in every cell of the body. The buildup of cystine causes kidney problems and the disease may lead to slow body growth and small stature, weak bones and developing and worsening kidney failure.

There are three types of cystinosis, the most severe being nephropathic cystinosis. Currently the FDA-approved drugs used to treat cystinosis include the cysteamine-based treatments Cystagon, an immediate-release tablet marketed by Mylan and approved in 1994, and Sigma-Tau's Cystaran eye drops, approved last year to treat corneal cystine crystal accumulation.

Procysbi (cysteamine bitartrate) is a delayed-release capsule intended for patients ages six and older. While Cystagon is taken every six hours around the clock to control cystine levels, Procysbi is a long-acting formulation taken every 12 hours.

The major study supporting Procysbi’s safety and effectiveness involved 43 adults and children with nephropathic cystinosis. Patients were randomly assigned to receive Cystagon or Procysbi for three weeks before being switched to the other product for an additional three weeks and blood testing showed the Raptor treatment was as effective as Cystagon in controlling cystine levels.


Previous Page Next Page

People Searching On This Page:
  • Food and Drug Administration picture
  • fda drugs
  • us food and drug administration

Related Pages


Strides gets FDA approval to market skin disease drug in US

Strides gets FDA approval to market skin disease drug in US

News | FDA
Date:
05-Jul-2014  Views: 1246

Strides Arcolab has received regulatory approval to market a skin disease drug in the US.The US Food and Drug Administration (FDA) has allowed the com ...
Diet Pill Dilemma: Why Is FDA Approving Drugs When Europe Isn’t?

Diet Pill Dilemma: Why Is FDA Approving Drugs When Europe Isn’t?

News | FDA
Date:
09-Sep-2013  Views: 1789

We’ve all dreamt of popping a pill to help us safely lose weight, or at least eat that chocolate cake without guilt. But alas, even though the Food an ...
Glenmark gets USFDA nod for alcohol abstinence drug

Glenmark gets USFDA nod for alcohol abstinence drug

News | FDA
Date:
14-Aug-2013  Views: 8408

Glenmark Pharmaceuticals today said it has received US health regulator's approval to market generic version of Forest Laboratories' Campral Delayed R ...
FDA approves Simponi to treat ulcerative colitis

FDA approves Simponi to treat ulcerative colitis

News | FDA
Date:
23-Jul-2013  Views: 929

The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative co ...
Post Your Comments (No Login Require)
Name : (required)
Email : (required)
Website :

Comment : (required)

44  + 6 =     
Comments
People Searched About:
Food And Drug Administration Picture   |   Fda Drugs   |   Us Food And Drug Administration   |  
Google : 181 times | Yahoo : 15 times | Bing : 56 times |